Clinical trial
TAS-102 and Oxaliplatin (TAS-OX) for Refractory Metastatic Colon Cancer
NCT02848079 is registered in ClinicalTrials.gov with Yale University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- TAS-102 and Oxaliplatin (TAS-OX) for Refractory Metastatic Colon Cancer
- Lead sponsor
- Yale University
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 31, 2016
- Completion date
- June 2, 2020
- Enrollment
- 41 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.